Answers are grounded in this paper and cite their sources.
This update addresses obesity and metabolic syndrome in metabolic dysfunction-associated steatotic liver disease, highlighting diagnosis and management strategies.
Metabolic dysfunction–associated steatotic liver disease (MASLD) is the new name for nonalcoholic fatty liver disease and continues to be a significant global health care problem, commensurate with the increased prevalence of obesity and metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Osta et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: